Skip to main content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway

  • Katie Twigger1,
  • Victoria Roulstone1,
  • Joan Kyula1,
  • Eleni M Karapanagiotou1,
  • Konstantinos N Syrigos2,
  • Richard Morgan3,
  • Christine White1,
  • Shreerang Bhide1,
  • Gerard Nuovo4,
  • Matt Coffey5,
  • Brad Thompson5,
  • Adel Jebar6,
  • Fiona Errington6,
  • Alan A Melcher6,
  • Richard G Vile6, 7,
  • Hardev S Pandha3 and
  • Kevin J Harrington1, 8Email author
BMC Cancer201212:368

DOI: 10.1186/1471-2407-12-368

Received: 12 March 2012

Accepted: 2 August 2012

Published: 24 August 2012

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
12 Mar 2012 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
25 Apr 2012 Reviewed Reviewer Report - Wen-Ling Shih
2 May 2012 Reviewed Reviewer Report - Ronald Moore
25 Jun 2012 Author responded Author comments - Victoria Roulstone
Resubmission - Version 3
25 Jun 2012 Submitted Manuscript version 3
4 Jul 2012 Reviewed Reviewer Report - Wen-Ling Shih
12 Jul 2012 Reviewed Reviewer Report - Ronald Moore
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
2 Aug 2012 Editorially accepted
24 Aug 2012 Article published 10.1186/1471-2407-12-368

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Division of Cancer Biology Chester Beatty Laboratories, The Institute of Cancer Research
(2)
Department of Oncology, Sotiria General Hospital
(3)
Postgraduate Medical School, The University of Surrey
(4)
The Comprehensive Cancer Centre, Ohio State University
(5)
Oncolytics Biotech Inc
(6)
Leeds Institute of Molecular Medicine
(7)
Molecular Medicine Program, Mayo Clinic
(8)
Targeted Therapy Laboratory, Division of Cancer Biology, Institute of Cancer Research

Advertisement